Hantz Financial Services Inc. Buys 1,264 Shares of Cytokinetics, Incorporated $CYTK

Hantz Financial Services Inc. grew its stake in Cytokinetics, Incorporated (NASDAQ:CYTK) by 2,872.7% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,308 shares of the biopharmaceutical company’s stock after acquiring an additional 1,264 shares during the period. Hantz Financial Services Inc.’s holdings in Cytokinetics were worth $43,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of CYTK. Vestal Point Capital LP boosted its holdings in shares of Cytokinetics by 10.2% during the first quarter. Vestal Point Capital LP now owns 2,590,531 shares of the biopharmaceutical company’s stock worth $104,113,000 after acquiring an additional 240,531 shares during the period. Westfield Capital Management Co. LP grew its stake in shares of Cytokinetics by 2.4% during the first quarter. Westfield Capital Management Co. LP now owns 1,310,336 shares of the biopharmaceutical company’s stock worth $52,662,000 after buying an additional 30,346 shares during the last quarter. Brown Advisory Inc. grew its stake in shares of Cytokinetics by 0.9% during the first quarter. Brown Advisory Inc. now owns 1,086,300 shares of the biopharmaceutical company’s stock worth $43,658,000 after buying an additional 9,869 shares during the last quarter. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. grew its stake in shares of Cytokinetics by 571.2% during the second quarter. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. now owns 1,082,563 shares of the biopharmaceutical company’s stock worth $35,768,000 after buying an additional 921,278 shares during the last quarter. Finally, Aberdeen Group plc lifted its holdings in shares of Cytokinetics by 53.2% during the second quarter. Aberdeen Group plc now owns 922,929 shares of the biopharmaceutical company’s stock worth $30,494,000 after purchasing an additional 320,508 shares during the period.

Insider Activity at Cytokinetics

In other news, Director Wendell Wierenga sold 4,375 shares of the firm’s stock in a transaction dated Monday, October 27th. The shares were sold at an average price of $58.68, for a total value of $256,725.00. Following the completion of the sale, the director directly owned 32,444 shares of the company’s stock, valued at approximately $1,903,813.92. This trade represents a 11.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Edward M. Md Kaye sold 6,757 shares of the firm’s stock in a transaction dated Monday, October 6th. The stock was sold at an average price of $60.00, for a total transaction of $405,420.00. Following the completion of the sale, the director directly owned 9,778 shares of the company’s stock, valued at approximately $586,680. This represents a 40.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 56,983 shares of company stock valued at $3,165,356. 2.70% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on CYTK. Bank of America boosted their target price on shares of Cytokinetics from $52.00 to $56.00 and gave the company a “neutral” rating in a report on Thursday, October 2nd. JMP Securities reissued a “market outperform” rating and set a $78.00 target price on shares of Cytokinetics in a research report on Tuesday, September 2nd. Wall Street Zen raised shares of Cytokinetics from a “strong sell” rating to a “hold” rating in a research report on Sunday, August 10th. Stifel Nicolaus boosted their target price on shares of Cytokinetics from $87.00 to $96.00 and gave the company a “buy” rating in a research note on Tuesday, September 2nd. Finally, Raymond James Financial started coverage on shares of Cytokinetics in a research note on Wednesday, July 30th. They issued a “market perform” rating on the stock. Thirteen research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $76.64.

Cytokinetics Stock Performance

CYTK stock opened at $59.19 on Thursday. Cytokinetics, Incorporated has a 52 week low of $29.31 and a 52 week high of $64.13. The firm’s fifty day moving average is $54.31 and its 200 day moving average is $41.79. The firm has a market cap of $7.08 billion, a P/E ratio of -11.61 and a beta of 0.67.

Cytokinetics (NASDAQ:CYTK) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.12) EPS for the quarter, beating the consensus estimate of ($1.34) by $0.22. The business had revenue of $66.77 million for the quarter, compared to the consensus estimate of $1.95 million. Cytokinetics’s revenue for the quarter was up 26727.3% on a year-over-year basis. During the same period in the prior year, the business posted ($1.31) EPS. As a group, analysts forecast that Cytokinetics, Incorporated will post -5.24 EPS for the current year.

Cytokinetics Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.